CD274 and non-small cell lung carcinoma: In a study investigating atezolizumab plus chemotherapy for non-squamous NSCLC regardless of PD-L1 expression (IMpower132) [32], superior OS was also observed in Asian patients (Asian, hazard ratio [HR]: 0.42, 0.28–0.63; white, HR: 0.67, 0.54–0.84).